These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 10737486

  • 1. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
    Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM.
    J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
    [Abstract] [Full Text] [Related]

  • 2. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M, Stamey TA, McNeal JE, Yemoto CM.
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [Abstract] [Full Text] [Related]

  • 3. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
    Noguchi M, Stamey TA, Neal JE, Yemoto CE.
    J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
    [Abstract] [Full Text] [Related]

  • 4. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA, Katcher J, Levin HS, Klein EA.
    Int J Radiat Oncol Biol Phys; 1997 Mar 15; 37(5):1043-52. PubMed ID: 9169811
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.
    J Urol; 2002 Jul 15; 168(1):110-5. PubMed ID: 12050502
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC, SEARCH Database Study Group.
    J Urol; 2003 Jun 15; 169(6):2136-41. PubMed ID: 12771735
    [Abstract] [Full Text] [Related]

  • 14. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb 15; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun 15; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
    Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC.
    J Urol; 1998 Dec 15; 160(6 Pt 1):2089-95. PubMed ID: 9817330
    [Abstract] [Full Text] [Related]

  • 20. Biological determinants of cancer progression in men with prostate cancer.
    Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM.
    JAMA; 1999 Apr 21; 281(15):1395-400. PubMed ID: 10217055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.